Back to results
US 2025/0367222 A1Published application
Treatments for cancers driven by dnajb1-prkaca gene fusions
AssigneeWisconsin Alumni Research Foundation
InventorSean Ronnekleiv-Kelly
Life of this patent
Estimating the term…
Abstract
Treatments for cancers driven by DNAJB1-PRKACA gene fusions, including fibrolamellar carcinoma (FLC) and other cancers, specifically, with the use of CDK7 inhibitors either alone or in combination with other agents, such as CDK9 inhibitors.
Claims20
A method of treating a DNAJB1-PRKACA gene fusion-driven cancer in a subject, the method comprising administering a CDK7 inhibitor to the subject in an amount effective to treat the cancer.
A composition comprising a CDK7 inhibitor and one or more additional active agents comprising one or more of a CDK9 inhibitor and a B-cell lymphoma-extra large (Bcl-xL) inhibitor.
Dependencies are inferred from the claim text.